- Home
- OBIO vs IKT Comparison
OBIO vs IKT Comparison
Compare OBIO & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | IKT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 240.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OBIO | IKT |
|---|---|---|
| Price | $4.51 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $14.25 | $5.00 |
| AVG Volume (30 Days) | 165.7K | ★ 1.2M |
| Earning Date | 05-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.13 | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.43 | $33.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1169.22 | N/A |
| 52 Week Low | $2.20 | $1.33 |
| 52 Week High | $5.42 | $2.37 |
Technical Indicators
Market Signals| Indicator | OBIO | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 44.65 |
| Support Level | $4.02 | $1.43 |
| Resistance Level | $4.88 | $1.74 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 59.49 | 50.00 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.